Literature DB >> 23969698

Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma.

Joseph A DiDonato1, Ying Huang, Kulwant S Aulak, Orli Even-Or, Gary Gerstenecker, Valentin Gogonea, Yuping Wu, Paul L Fox, W H Wilson Tang, Edward F Plow, Jonathan D Smith, Edward A Fisher, Stanley L Hazen.   

Abstract

BACKGROUND: Prior studies show that apolipoprotein A1 (apoA1) recovered from human atherosclerotic lesions is highly oxidized. Ex vivo oxidation of apoA1 or high-density lipoprotein (HDL) cross-links apoA1 and impairs lipid binding, cholesterol efflux, and lecithin-cholesterol acyltransferase activities of the lipoprotein. Remarkably, no studies to date directly quantify either the function or HDL particle distribution of apoA1 recovered from the human artery wall. METHODS AND
RESULTS: A monoclonal antibody (10G1.5) was developed that equally recognizes lipid-free and HDL-associated apoA1 in both native and oxidized forms. Examination of homogenates of atherosclerotic plaque-laden aorta showed >100-fold enrichment of apoA1 compared with normal aorta (P<0.001). Surprisingly, buoyant density fractionation revealed that only a minority (<3% of total) of apoA1 recovered from either lesions or normal aorta resides within an HDL-like particle (1.063≤d≤1.21). In contrast, the majority (>90%) of apoA1 within aortic tissue (normal and lesions) was recovered within the lipoprotein-depleted fraction (d>1.21). Moreover, both lesion and normal artery wall apoA1 are highly cross-linked (50% to 70% of total), and functional characterization of apoA1 quantitatively recovered from aorta with the use of monoclonal antibody 10G1.5 showed ≈80% lower cholesterol efflux activity and ≈90% lower lecithin-cholesterol acyltransferase activity relative to circulating apoA1.
CONCLUSIONS: The function and distribution of apoA1 in human aorta are quite distinct from those found in plasma. The lipoprotein is markedly enriched within atherosclerotic plaque, predominantly lipid-poor, not associated with HDL, extensively oxidatively cross-linked, and functionally impaired.

Entities:  

Keywords:  apolipoproteins; arteriosclerosis; cardiovascular diseases; plaque, atherosclerotic

Mesh:

Substances:

Year:  2013        PMID: 23969698      PMCID: PMC3882895          DOI: 10.1161/CIRCULATIONAHA.113.002624

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  49 in total

1.  [Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].

Authors:  A Vogt; U Kassner; U Hostalek; A Peiter; E Steinhagen-Thiessen
Journal:  MMW Fortschr Med       Date:  2006-05-04

Review 2.  Lecithin-cholesterol acyltransferase. Assay of cholesterol esterification and phospholipase A2 activities.

Authors:  J S Parks; A K Gebre; J W Furbee
Journal:  Methods Mol Biol       Date:  1999

3.  Transport pathways of beta-VLDL by aortic endothelium of normal and hypercholesterolemic rabbits.

Authors:  E Vasile; F Antohe; M Simionescu; N Simionescu
Journal:  Atherosclerosis       Date:  1989-02       Impact factor: 5.162

4.  Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities.

Authors:  Dao-Quan Peng; Zhiping Wu; Gregory Brubaker; Lemin Zheng; Megan Settle; Eitan Gross; Michael Kinter; Stanley L Hazen; Jonathan D Smith
Journal:  J Biol Chem       Date:  2005-08-08       Impact factor: 5.157

5.  Intimal thickenings of human aorta contain modified reassembled lipoproteins.

Authors:  D Tîrziu; A Dobrian; C Tasca; M Simionescu; N Simionescu
Journal:  Atherosclerosis       Date:  1995-01-06       Impact factor: 5.162

6.  Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase.

Authors:  J W Chisholm; A K Gebre; J S Parks
Journal:  J Lipid Res       Date:  1999-08       Impact factor: 5.922

7.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

8.  Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages.

Authors:  Lemin Zheng; Megan Settle; Gregory Brubaker; Dave Schmitt; Stanley L Hazen; Jonathan D Smith; Michael Kinter
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

9.  Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport.

Authors:  Baohai Shao; Constanze Bergt; Xiaoyun Fu; Pattie Green; John C Voss; Michael N Oda; John F Oram; Jay W Heinecke
Journal:  J Biol Chem       Date:  2004-11-30       Impact factor: 5.157

10.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

View more
  37 in total

1.  Apolipoprotein A-I and cholesterol efflux: the good, the bad, and the modified.

Authors:  Ali Javaheri; Daniel J Rader
Journal:  Circ Res       Date:  2014-05-23       Impact factor: 17.367

2.  Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.

Authors:  Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

3.  Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.

Authors:  Bernd Hewing; Saj Parathath; Tessa Barrett; Wing Ki Kellie Chung; Yaritzy M Astudillo; Tadateru Hamada; Bhama Ramkhelawon; Thomas C Tallant; Mohamed Shaif S Yusufishaq; Joseph A Didonato; Ying Huang; Jennifer Buffa; Stela Z Berisha; Jonathan D Smith; Stanley L Hazen; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-09       Impact factor: 8.311

4.  HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function.

Authors:  Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith
Journal:  J Lipid Res       Date:  2015-01-05       Impact factor: 5.922

Review 5.  LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?

Authors:  Bernd Hewing; Ulf Landmesser
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

6.  Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL.

Authors:  Naoko Sawada; Takashi Obama; Shinji Koba; Takashi Takaki; Sanju Iwamoto; Toshihiro Aiuchi; Rina Kato; Masaki Kikuchi; Yuji Hamazaki; Hiroyuki Itabe
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

7.  Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosis.

Authors:  Giorgio Cavigiolio; Shobini Jayaraman
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

8.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

9.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

10.  High-density lipoprotein-mediated transcellular cholesterol transport in mouse aortic endothelial cells.

Authors:  LiXia Miao; Emmanuel U Okoro; ZhiJan Cao; Hong Yang; Evangeline Motley-Johnson; Zhongmao Guo
Journal:  Biochem Biophys Res Commun       Date:  2015-08-07       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.